A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

ABSTRACT: ATRC-101-A01 is a Phase 1b, open-label dose escalation and expansion trial of ATRC-101, an engineered fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally occurring human antibody. The safety, tolerability, PK, and biological activity of ATRC-101 will be characterized when administered every two weeks (Q2W) or every 3 weeks (Q3W) as a monotherapy or in combination with other anticancer agents.

DISEASE(S): Carcinoma,Dmmr Colorectal Cancer,Triple Negative Breast Neoplasms,Melanoma,Colorectal Cancer,Urothelial Carcinoma,Triple Negative Breast Cancer,Msi-h Colorectal Cancer,Breast Neoplasms,Breast Cancer,Ovarian Cancer,Acral Lentiginous Melanoma,Carcinoma, Squamous Cell,Squamous Cell Carcinoma Of Head And Neck,Platinum-resistant Fallopian Tube Carcinoma,Non-small Cell Lung Cancer,Carcinoma, Ovarian Epithelial,Colorectal Neoplasms,Platinum-resistant Epithelial Ovarian Cancer,Platinum-resistant Primary Peritoneal Carcinoma,Ovarian Neoplasms,Head And Neck Squamous Cell Carcinoma,Hepatocellular Carcinoma,Esophageal Squamous Cell Carcinoma

PROVIDER: 2328187 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR